The Alliance for Health Reforms Bangladesh (AHRB) has urged the Chief Adviser to prioritize and directly oversee the swift implementation of the Active Pharmaceutical Ingredient (API) policy, calling it a matter of national strategic interest. In an open letter sent on December 7, AHRB leaders emphasized that while Bangladesh can produce most medicines domestically, the country remains heavily dependent on imported APIs, leaving its health security vulnerable to global market disruptions. The letter, signed by Professor Syed Abdul Hamid and Professor Syed Md. Akram Hossain, highlighted lessons from the successful 1982 National Drug Policy, noting that strong political commitment and leadership were key to transforming the sector. The AHRB proposed five urgent measures: removing administrative barriers, introducing a production-linked incentive scheme, ensuring continuous R&D funding, strengthening academia–industry collaboration, and forming a permanent empowered task force. Experts argue that developing domestic API capacity could reduce import dependence, save foreign currency, and expand exports. They stress that without knowledge-based industrial transformation, Bangladesh’s tax-to-GDP ratio will remain low, limiting economic resilience.
বাংলাদেশের ওষুধশিল্পকে কৌশলগতভাবে রূপান্তর এবং জাতীয় স্বাস্থ্য–নিরাপত্তা জোরদার করতে অ্যাকটিভ ফার্মাসিউটিক্যাল ইনগ্রেডিয়েন্ট (এপিআই) নীতি দ্রুত বাস্তবায়নের আহ্বান জানিয়েছে অ্যালায়েন্স ফর হেলথ রিফর্মস বাংলাদেশ (এএইচআরবি)। এই নীতি বাস্তবায়নে প্রধান উপদ
The ‘1 Nojor’ media platform is now live in beta, inviting users to explore and provide feedback as we continue to refine the experience.
